192 related articles for article (PubMed ID: 36542574)
21. SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction.
Slíva J
Vnitr Lek; 2022; 68(6):393-397. PubMed ID: 36316201
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
24. Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.
Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
Am J Cardiol; 2022 Sep; 179():111-114. PubMed ID: 35871863
[No Abstract] [Full Text] [Related]
25. Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient.
Essa H; Walker L; Sankaranarayanan R
Br J Clin Pharmacol; 2022 Jun; 88(6):2566-2570. PubMed ID: 34622474
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
Volpe M; Pedicino D
Eur Heart J; 2022 Nov; 43(44):4614-4615. PubMed ID: 36173867
[No Abstract] [Full Text] [Related]
27. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
Volpe M; Gallo G
Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
[No Abstract] [Full Text] [Related]
28. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
Bauersachs J; Soltani S
Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060
[No Abstract] [Full Text] [Related]
29. Sodium-glucose cotransporter 2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: time to deliver implementation.
Greene SJ; Fonarow GC; Butler J
Eur J Heart Fail; 2022 Oct; 24(10):1902-1905. PubMed ID: 36097872
[No Abstract] [Full Text] [Related]
30. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
[TBL] [Abstract][Full Text] [Related]
31. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
Liang B; Gu N
Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
[TBL] [Abstract][Full Text] [Related]
32. Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2is) Following FDA Approval for Heart Failure With Preserved and Mildly Reduced Ejection Fraction.
Martyn T; Saef J; Bansal A; Martinez KA; Block-Beach H; Hohman J; Kapadia SR; Desai MY; Estep JD; Albert NM; Starling RC; Tang WHW
J Card Fail; 2024 Apr; 30(4):630-632. PubMed ID: 38367905
[No Abstract] [Full Text] [Related]
33. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
34. Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
Packer M; Zannad F
J Card Fail; 2022 Apr; 28(4):682-683. PubMed ID: 35038597
[No Abstract] [Full Text] [Related]
35. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
36. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.
Liang B; Liang Y; Gu N
BMC Cardiovasc Disord; 2022 Jun; 22(1):261. PubMed ID: 35689186
[TBL] [Abstract][Full Text] [Related]
37. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
Crea F
Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
[No Abstract] [Full Text] [Related]
38. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
[TBL] [Abstract][Full Text] [Related]
39. Obese or lean: Whom to prescribe sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction?
Halavina K; Bartko PE; Nitsche C
Eur J Heart Fail; 2024 Apr; 26(4):910-911. PubMed ID: 38679836
[No Abstract] [Full Text] [Related]
40. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Caruso I; Cignarelli A; Laviola L; Giorgino F
Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
